566 related articles for article (PubMed ID: 23358121)
1. Evaluation of seven noninvasive models in staging liver fibrosis in patients with chronic hepatitis B virus infection.
Ma J; Jiang Y; Gong G
Eur J Gastroenterol Hepatol; 2013 Apr; 25(4):428-34. PubMed ID: 23358121
[TBL] [Abstract][Full Text] [Related]
2. APRI, the FIB-4 score, and Forn's index have noninvasive diagnostic value for liver fibrosis in patients with chronic hepatitis B.
Ucar F; Sezer S; Ginis Z; Ozturk G; Albayrak A; Basar O; Ekiz F; Coban S; Yuksel O; Armutcu F; Akbal E
Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1076-81. PubMed ID: 23510962
[TBL] [Abstract][Full Text] [Related]
3. Can we predict the degree of fibrosis in chronic hepatitis C patients using routine blood tests in our daily practice?
Cheung RC; Currie S; Shen H; Bini EJ; Ho SB; Anand BS; Hu KQ; Wright TL; Morgan TR;
J Clin Gastroenterol; 2008 Aug; 42(7):827-34. PubMed ID: 18285716
[TBL] [Abstract][Full Text] [Related]
4. The diagnostic value of non-invasive tests for the evaluation of liver fibrosis in chronic hepatitis B patients.
Erdogan S; Dogan HO; Sezer S; Uysal S; Ozhamam E; Kayacetin S; Koca Y
Scand J Clin Lab Invest; 2013; 73(4):300-8. PubMed ID: 23514016
[TBL] [Abstract][Full Text] [Related]
5. APRI and FIB-4 are good predictors of the stage of liver fibrosis in chronic hepatitis B: the Chronic Hepatitis Cohort Study (CHeCS).
Teshale E; Lu M; Rupp LB; Holmberg SD; Moorman AC; Spradling P; Vijayadeva V; Boscarino JA; Schmidt MA; Gordon SC;
J Viral Hepat; 2014 Dec; 21(12):917-20. PubMed ID: 25131445
[TBL] [Abstract][Full Text] [Related]
6. Noninvasive models to predict liver cirrhosis in patients with chronic hepatitis B.
Kim BK; Kim SA; Park YN; Cheong JY; Kim HS; Park JY; Cho SW; Han KH; Chon CY; Moon YM; Ahn SH
Liver Int; 2007 Sep; 27(7):969-76. PubMed ID: 17696936
[TBL] [Abstract][Full Text] [Related]
7. Non-invasive tests in prediction of liver fibrosis in chronic hepatitis B and comparison with post-antiviral treatment results.
Başar O; Yimaz B; Ekiz F; Giniş Z; Altinbaş A; Aktaş B; Tuna Y; Çoban S; Delibaş N; Yüksel O
Clin Res Hepatol Gastroenterol; 2013 Apr; 37(2):152-8. PubMed ID: 23391746
[TBL] [Abstract][Full Text] [Related]
8. Serum Biomarkers Predictive of Significant Fibrosis and Cirrhosis in Chronic Hepatitis B.
Lin CL; Liu CH; Wang CC; Liang CC; Su TH; Liu CJ; Kao JH
J Clin Gastroenterol; 2015 Sep; 49(8):705-13. PubMed ID: 25319739
[TBL] [Abstract][Full Text] [Related]
9. [Comparison of various noninvasive serum markers of liver fibrosis in chronic viral liver disease].
Kim SM; Sohn JH; Kim TY; Roh YW; Eun CS; Jeon YC; Han DS; Oh YH
Korean J Hepatol; 2009 Dec; 15(4):454-63. PubMed ID: 20037264
[TBL] [Abstract][Full Text] [Related]
10. Assessment of non-invasive models for liver fibrosis in chronic hepatitis B virus related liver disease patients in resource limited settings.
Shrivastava R; Sen S; Banerji D; Praharaj AK; Chopra GS; Gill SS
Indian J Pathol Microbiol; 2013; 56(3):196-9. PubMed ID: 24152493
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic accuracy of transient elastography (FibroScan) versus the aspartate transaminase to platelet ratio index in assessing liver fibrosis in chronic hepatitis B: the role in primary care setting.
Lesmana CR; Salim S; Hasan I; Sulaiman AS; Gani RA; Pakasi LS; Lesmana LA; Krisnuhoni E; Budihusodo U
J Clin Pathol; 2011 Oct; 64(10):916-20. PubMed ID: 21670074
[TBL] [Abstract][Full Text] [Related]
12. Clinical usefulness of mean platelet volume and red blood cell distribution width to platelet ratio for predicting the severity of hepatic fibrosis in chronic hepatitis B virus patients.
Karagoz E; Ulcay A; Tanoglu A; Kara M; Turhan V; Erdem H; Oncul O; Gorenek L
Eur J Gastroenterol Hepatol; 2014 Dec; 26(12):1320-4. PubMed ID: 25210777
[TBL] [Abstract][Full Text] [Related]
13. Is there any non-invasive marker replace the needle liver biopsy predictive for liver fibrosis, in patients with chronic hepatitis?
Vardar R; Vardar E; Demiri S; Sayhan SE; Bayol U; Yildiz C; Postaci H
Hepatogastroenterology; 2009; 56(94-95):1459-65. PubMed ID: 19950810
[TBL] [Abstract][Full Text] [Related]
14. The validity of serum markers for fibrosis staging in chronic hepatitis B and C.
Li J; Gordon SC; Rupp LB; Zhang T; Boscarino JA; Vijayadeva V; Schmidt MA; Lu M;
J Viral Hepat; 2014 Dec; 21(12):930-7. PubMed ID: 24472062
[TBL] [Abstract][Full Text] [Related]
15. Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients.
Kim BK; Kim DY; Park JY; Ahn SH; Chon CY; Kim JK; Paik YH; Lee KS; Park YN; Han KH
Liver Int; 2010 Apr; 30(4):546-53. PubMed ID: 20074094
[TBL] [Abstract][Full Text] [Related]
16. [Retrospective study of FibroScan, APRI, FIB-4 and FORNS indexes compared with liver biopsy in the evaluation of liver fibrosis in patients with chronic hepatitis C monoinfection and HIV coinfection].
González Guilabert MI; Hinojosa Mena-Bernal C; del Pozo González J; del Pozo Pérez MA
Gastroenterol Hepatol; 2010; 33(6):425-32. PubMed ID: 20471720
[TBL] [Abstract][Full Text] [Related]
17. [A noninvasive model to predict histological liver cirrhosis in patients with chronic hepatitis B].
Tu XL; Xiao YQ; Chen F
Zhonghua Gan Zang Bing Za Zhi; 2009 Jan; 17(1):28-32. PubMed ID: 19203448
[TBL] [Abstract][Full Text] [Related]
18. Role of AST to platelet ratio index in the detection of liver fibrosis in patients with recurrent hepatitis C after liver transplantation.
Toniutto P; Fabris C; Bitetto D; Falleti E; Avellini C; Rossi E; Smirne C; Minisini R; Pirisi M
J Gastroenterol Hepatol; 2007 Nov; 22(11):1904-8. PubMed ID: 17914968
[TBL] [Abstract][Full Text] [Related]
19. Value of gamma-glutamyltranspeptidase-to-platelet ratio in diagnosis of hepatic fibrosis in patients with chronic hepatitis B.
Hu YC; Liu H; Liu XY; Ma LN; Guan YH; Luo X; Ding XC
World J Gastroenterol; 2017 Nov; 23(41):7425-7432. PubMed ID: 29151696
[TBL] [Abstract][Full Text] [Related]
20. Changes in APRI and FIB-4 in HBeAg-negative treatment-naive chronic hepatitis B patients with significant liver histological lesions receiving 5-year entecavir therapy.
Liu R; Guo J; Lu Y; Zhang L; Shen G; Wu S; Chang M; Hu L; Hao H; Li M; Xie Y
Clin Exp Med; 2019 Aug; 19(3):309-320. PubMed ID: 31111345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
